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Abstract
Rationale: It is widely believed that glycosaminoglycans (GAGs) and bound plasma proteins form an interconnected gel-like
structure on the surface of endothelial cells (the endothelial glycocalyx layer–EGL) that is stabilized by the interaction of its
components. However, the structural organization of GAGs and proteins and the contribution of individual components to
the stability of the EGL are largely unknown.
Objective: To evaluate the hypothesis that the interconnected gel-like glycocalyx would collapse when individual GAG
components were almost completely removed by a specific enzyme.
Methods and Results: Using confocal microscopy, we observed that the coverage and thickness of heparan sulfate (HS),
chondroitin sulfate (CS), hyaluronic acid (HA), and adsorbed albumin were similar, and that the thicknesses of individual
GAGs were spatially nonuniform. The individual GAGs were degraded by specific enzymes in a dose-dependent manner,
and decreased much more in coverage than in thickness. Removal of HS or HA did not result in cleavage or collapse of any
of the remaining components. Simultaneous removal of CS and HA by chondroitinase did not affect HS, but did reduce
adsorbed albumin, although the effect was not large.
Conclusion: All GAGs and adsorbed proteins are well inter-mixed within the structure of the EGL, but the GAG components
do not interact with one another. The GAG components do provide binding sites for albumin. Our results provide a new
view of the organization of the endothelial glycocalyx layer and provide the first demonstration of the interaction between
individual GAG components.
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Introduction
The luminal surfaces of vascular endothelium are covered by an
endothelial glycocalyx layer (EGL) which serves as a transport and
adhesion barrier and plays important roles in the mechanotrans-
duction of shear stress [1–4]. A cartoon that integrates all of the
components of the glycocalyx was described in our previous paper
[2]. The glycocalyx is comprised of a variety of macromolecules,
including glycoproteins bearing acidic oligosaccharides and
terminal sialic acids (SA), and proteoglycans (PGs) with glycos-
aminoglycan (GAG) side chains. GAGs are linear polydisperse
heteropolysaccharides, characterized by distinct disaccharide unit
repeats. Specific combinations of these give rise to different GAG
families, including heparan sulfate (HS), chondroitin sulfate (CS)
and hyaluronic acid (HA, also known as hyaluronan). In the
vasculature, the most prominent GAGs on the surface of
endothelial cells (ECs) are HS, accounting for more than 50% of
the total GAG pool, the rest being comprised of CS and HA.
The polyanionic nature of the constituents of the EGL imparts
to it a net negative charge [4]. HS and CS are largely responsible
for its anionic charge and are covalently linked to PGs. PGs are
synthesized in the Golgi apparatus, and are either secreted, bound
to the cell surface or stored in intracellular compartments [5]. A
single PG core protein can bind with multiple chains of HS and
CS in EGL [6]. The proportion of HS to CS chains has been
shown to be on the order of 4:1 in normal murine mammary gland
epithelial cells and was reduced to about 5:4 in the presence of
transforming growth factor-b (TGF-b), although the amount of
PG core proteins remained relatively unchanged [7]. In both
bovine aortic endothelial cells (BAEC) and human aortic
endothelial cells (HAEC), 30 mM glucose treatment resulted in a
decrease of HS, but not CS or perlecan [8]. Similarly, in
glomerular ECs, 25.5 mM glucose induced a 50% reduction of
HS immuno-fluorescence intensity relative to 5.5 mM glucose, but
no reduction in PG core proteins [9]. All of those studies suggest
that HS and CS GAGs play very important roles in the structure
and function of the EGL.
HA is a non-sulphated GAG that is not covalently bound to a
core protein. HA is usually much longer than protein attached
GAGs [10]. Long chains of HA, attached to endothelial
membrane bound receptors, such as CD44, are presumed to
intertwine through the glycocalyx and provide part of the scaffold
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for the EGL [11]. In rat vascular endothelium, HA has been
shown to be scattered over the plasma membrane and concen-
trated in caveolae [12].
Plasma proteins also contribute to the structural organization of
the EGL, including albumin and orosomucoid [13]. Studies have
demonstrated the binding of albumin to the endothelial surface
using techniques of electron microscopy [14], intravital fluores-
cence microscopy [15] and confocal fluorescence microscopy [16].
In the presence of physiological albumin concentrations, fibrino-
gen binding to intact BAECs is greatly diminished [17]. Our
recent in vitro investigation using cryo-EM demonstrated that the
morphology of the EGL is mesh-like [16]. It has been presumed
that a cross-linked mesh created by the interaction among
membrane-bound PGs, plasma proteins, and soluble PGs,
contribute to the stability of the EGL [6].
The glycocalyx is rapidly and continuously shed and synthe-
sized, which facilitates endothelial adaptation to changes in the
local environment [18–20]. In disease states such as inflammation
[21,22], atherosclerosis [22], endotoxemia [23], and septic shock
[24], the EGL remains in a diminished state. Recent studies
explored the EGL function by direct removal of selected
components of the glycocalyx with specific enzymes. Interestingly,
different specific enzyme treatments resulted in distinct functions
of the EGL in both mechanotransduction [25] and permeability
[26,27]. We previously demonstrated that a 2 hr pretreatment
with 15 mU/mL heparinase III, 15 mU/mL chondroitinase ABC,
15 mU/mL neuraminidase, and 1.5 U/mL hyaluronidase, re-
spectively removed 42.6% HS, 44.2% CS, 38.4% SA, and 61.7%
HA in cultured BAEC, and found that shear-induced nitric oxide
(NO) production was blocked in the presence of those enzymes
except for chondroitinase ABC [25]. In addition, other experi-
ments suggest a layered EGL structure with different components
modulating both solute and cell penetration into the layer. For
example, treatment with 140 U/mL hyaluronidase for 1 hr in
hamster cremaster muscle microvessels enhanced the penetration
of 70-and 145-kDa dextrans, but did not affect the exclusion of red
cells and anionic proteins, showing that significant components of
the barrier remained in this tissue after hyaluronidase treatment
[11,27]. On the other hand, in the same vessels, treatment with
heparinase (1 mg/mL) caused a significant increase in the
penetration of red cells [28]. Recently, Gao and Lipowsky [26]
reported that a 10 min perfusion with 10 U/mL chondroitinase
ABC and 3000 U/mL hyaluronidase solution in the post-capillary
venules of the rat mesentery, significantly increased the penetra-
tion of 70 kDa dextrans, but a perfusion with 50 U/mL
heparinase III decreased it. Enzymatic treatment of the glycocalyx
can also facilitate adhesion of leucocytes to the endothelium
[29,30]. Additionally, Nikmanesh et al [31] demonstrated that
applying 15 mU/mL heparinase III to degrade HS on embryonic
stem cells, abolished the shear stress-induced expression of several
characteristic EC genes: vWF, VE-cadherin, ZO-1, eNOS, and
COX-2. Overall, most previous investigations focused changes in
the function of the EGL after specific enzyme treatments.
However, the mechanisms underlying those changes in function,
and the alterations in organization and spatial distribution of
glycocalyx components induced by enzyme treatments are less well
understood.
It is widely believed that the negatively charged GAGs capture
circulating plasma protein and form an interconnected gel-like
structure in an aqueous environment [4,32–34]. In the present
study, we tested whether depletion of a GAG component with a
specific enzyme would affect the distribution and thickness of other
GAG components as well as adsorbed proteins. The hypothesis
was that the glycocalyx would collapse when a GAG component
was reduced below a critical level. To test this hypothesis, we used
heparinase III, hyaluronidase, and chondroitinase ABC to deplete
individual GAGs, and imaged HS, CS, HA and adsorbed albumin
with immuno-fluorescent confocal microscopy.
Materials and Methods
Cell Culture
Rat fat pad endothelial cells (RFPECs) were cloned from cells
originally isolated from rat epididymal fat pad (a gift from Dr.
David C. Spray, Albert Einstein College of Medicine, Bronx, NY)
[35]. As previously described [16,36], RFPECs were cultured at
37uC with 5% CO2 in Dulbecco’s Modified Eagle Medium
(DMEM, Invitrogen, USA) supplemented with 10% fetal bovine
serum (FBS, Invitrogen, USA), and 1% penicillin-streptomycin.
Cells between passages 22 and 30 were then seeded onto glass
bottom dishes (MatTek, USA) until confluence (2,3 days).
Heparinase III Treatments
F. heparinum Heparinase III (IBEX, Canada) is selectively active
only towards HS [37]. For HS staining after enzyme treatment,
RFPEC monolayers were pretreated with 1 mL experimental
media containing 0 (control), 15, 45, 135, 405, 1215, and
3645 mU/mL heparinase III for 2 hr. For other GAG component
staining after enzyme treatment, RFPEC monolayers were
pretreated with 1 mL experimental media containing 0 (control),
135, and 1215 mU/mL heparinase III for 2 hr. The experimental
media was prepared using phenol red free DMEM containing 5%
FBS and 0.5% bovine serum albumin (BSA, sigma), pH 7.3.
Hyaluronidase Treatments
Although many hyaluronidases are capable of degrading CS
[38], hyaluronidase from Streptomyces hyalurolyticus (Sigma, USA) is
specific for HA and is inactive against CS. For HA staining after
enzyme treatment, RFPEC monolayers were pretreated with
1 mL experimental media containing 0 (control), 1.5, 4.5, and
13.5 U/mL hyaluronidase for 2 hr. For other GAG component
staining after enzyme treatment, RFPEC monolayers were
pretreated with 1 mL experimental media containing 0 (control),
1.5, and 4.5 U/mL hyaluronidase for 2 hr. The experimental
media was prepared using phenol red free DMEM containing 5%
FBS and 0.5% BSA, pH 7.3.
Chondroitinase ABC Treatments
P. vulgaris chondroitinase ABC (Sigma, USA) catalyzes the
eliminative degradation of CS and HA [39,40]. Importantly, there
is no chondroitinase available that reacts with CS, but not with
HA. For CS staining after enzyme treatment, RFPEC monolayers
were pretreated with 1 mL experimental media containing 0
(control), 15, 45, 135, and 405 mU/mL chondroitinase ABC for
2 hr. For other GAG component staining after enzyme treatment,
RFPEC monolayers were pretreated with 1 mL experimental
media containing 0 (control), 15, and 405 mU/mL chondroitinase
ABC for 2 hr. The experimental media was prepared using phenol
red free DMEM containing 5% FBS, 0.5% BSA, pH 7.3, and
60 mM sodium acetate.
Immunofluorescence Staining
In order to assess structural changes of the EGL, immunoflu-
orescence staining was performed on the enzyme treated RFPEC
monolayers.
Staining of HS. The RFPEC monolayers were quickly
washed one time with 16Dulbecco’s phosphate-buffered saline
(DPBS) and fixed with 2% paraformaldehyde/0.1% glutaralde-
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Figure 1. The methods for image quantification analysis. The 3D reconstruction of the Z-series stack (A), the split green channel (HS) (B), and
blue channel (DAPI) (C). (D–E) XZ-slice images along the dashed line in (A) and (B). (F) The max-intensity Z-projection of HS. The red outline in (C) and
the circles in (F) show the nuclei and cell body of the same two cells. The red arrow in (F) indicates the junction between these cells. The white arrow
heads in (D) and (E) indicate the cell-cell junctions along the slice. (G) The frequency curves of pixel intensity from the max-intensity Z-projection
images of both control and negative control (no antibody). The non-zero point of intersection between the curves was defined as the background
threshold. All information equal to or higher than background was selected as a region of interest (ROI). (H) The maximum coverage was usually
obtained at threshold. (I) top: the split green channel (HS) XZ-slice; middle: the red region shows the ROI in the XZ-slice at threshold; bottom:
negative control, the area of the ROI in XZ-slices was usually zero at threshold. (J) The area of a region bounded by a red outline (DA’) and the width
of the region’s bounding box (DL). The total area and length of all regions represent the area (A’) and the length (L), respectively, of the ROI
Endothelial Glycocalyx Structure
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hyde for 30 min at RT, then blocked with 2% Goat serum (GS,
Invitrogen, USA) for 30 min followed by an overnight incubation
at 4uC with mouse monoclonal primary antibody (1:100; 10E4
epitope, AMS Biotechnology, USA; or HepSS-1, US Biological,
USA), washed three times in 16DPBS, and finally incubated with
Alexa Fluor 488 goat anti-mouse secondary antibody (1:400;
Molecular Probes, USA) for 30 min at RT followed by three
washes in 16DPBS.
Staining of HA. The RFPEC monolayers were quickly
washed one time with 16DPBS and fixed with 2% paraformal-
dehyde/0.1% glutaraldehyde for 30 min at RT, then blocked with
2% GS in 16DPBS without calcium and magnesium for 30 min
followed by an overnight incubation at 4uC with biotinylated
hyaluronic acid binding protein (HABP; 50 mg/mL; EMD
Chemicals, USA), washed three times in 16DPBS, and finally
incubated with Alexa Fluor 488 anti-Biotin (1:100; Jackson
ImmunoResearch Lab, USA) for 30 min at RT followed by three
washes in 16DPBS.
Lectin labeling. The B.simplicifolia lectin II (GSL II) can
recognize exclusively a- or b-linked N-acetylglucosamine residues
present on CS. The RFPEC monolayers were quickly washed one
time with 16DPBS and incubated with biotinylated GSL II
(100 mg/cm2 in 16DPBS without calcium and magnesium;
Vector Labs, USA) for 15 min on ice, then incubated for
30 min with Alexa Fluor 488 anti-Biotin (1:100 in 16DPBS)
followed by three washes in 16DPBS.
Staining of BSA. The RFPEC monolayers were quickly
washed one time with 16DPBS and fixed with 2% paraformal-
dehyde/0.1% glutaraldehyde for 30 min at RT, then blocked with
2% GS for 30 min followed by an overnight incubation at 4uC
with anti-BSA (rabbit IgG, 1:300; Molecular Probes, USA),
washed three times in 16DPBS, and finally incubated with Alexa
Fluor 488 goat anti-rabbit secondary antibody (1:400; Molecular
Probes, USA) for 30 min at RT followed by three washes in
16DPBS.
Antibodies were diluted in blocking buffer unless indicated
otherwise. Finally, cells were mounted in Aqua-Poly/Mount
coverslipping medium (Polysciences, USA). Negative controls
were prepared without the primary antibodies or binding proteins.
Detailed information about antibodies that were used in the
present study is described in Discussion S1 (Figures S4, S5, and
S6).
Confocal Microscope and Data Acquisition
All samples were imaged with a Zeiss LSM 510 laser scanning
confocal microscope (Confocal Microscopy Laboratory, The City
College of New York, NY) using a Plan-Neofluar 406/1.3 Oil
DIC or Plan-Apochromat 636/1.4 Oil DIC objective. The field of
view (FOV) was approximately 210.46210.4 (406) or
133.66133.6 mm2 (636), captured into an 8 bit file with a
5126512 pixel resolution. The Alexa Fluor 488 fluorescence was





DL). The average thickness (TAV ~A’=L) in this slice is 2.23 mm. (K–L) Partial enlargement of the XZ-slice image with a junctional
thickness measure line. The half-maximum intensity value was employed as the 2nd threshold for junctional thickness detection. In this image, the
signal-to-noise ratio is 9.11, and the junction thickness of HS is 3.00 mm.
doi:10.1371/journal.pone.0043168.g001
Figure 2. The distribution of HS on RFPECs after 2 hr heparinase III treatment. (A) top: Z-projection; bottom: cross-sectional images of stack
along the dashed line. The arrow head indicates the cell-cell junction. Scale bar: 20 mm. (B) The changes in coverage; (C) the average thickness; (D) the
junction thickness. HepSS-1 epitope HS-antibodies were used. The coverage, average thickness, and junction thickness were significantly decreased
with increasing concentration of heparinase III. **P,0.01.
doi:10.1371/journal.pone.0043168.g002
Endothelial Glycocalyx Structure
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through the 505–550 nm band-pass emission filter. The DAPI was
excited by a 405 nm diode laser, and filtered through the 420–
480 nm band-pass emission filter. For each type of staining, the
laser transmission and laser gain levels were adjusted just below
the fluorophore saturation level, and then were applied for the
acquisition of all images. The pinhole size of the Alexa Fluor 488
channel was set to 1 Airy unit for the best compromise between
depth discrimination and efficiency, and then that of the DAPI
channel was adjusted so that each channel had the same ‘‘optical
slice’’. To obtain a Z-series stack, the interval between slices was
either 0.3 or 0.36 mm.
Image Quantification Analysis
Using ImageJ software (version 1.46; NIH, USA), the split and
recombination (mergence) of color channels, and three-dimen-
sional reconstruction of the Z-series stack were performed
(Figure 1A, B and C). The orthogonal XZ-and YZ-slices were
reconstructed through the image volume represented by the Z-
series stack (Figure 1D and E). The maximum intensity Z-
projection of the green Z-series stack (Alexa Fluor 488 channel)
was created, in which each pixel contains the maximum value over
all images in the stack at the particular pixel location, showing all
the staining in a given FOV (Figure 1F).
Figure 3. The quantification of HA, CS, and albumin on RFPECs after 2 hr heparinase III treatment. (A)–(C) The changes in the coverage,
the average thickness, and the junction thickness of HA; (D)–(F) CS; (G)–(I) adsorbed albumin. *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0043168.g003
Endothelial Glycocalyx Structure
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Background noise and threshold. The pixel intensity
histograms from the FOV of max-intensity Z-projection images
of control and negative control were obtained using the ImageJ
histogram tool, and converted to curves (Figure 1G). The
maximum intensity value in 8-bit images was 255. The point of
intersection between the curves was defined as the background
noise value (threshold). All information equal to or higher than
background was selected as a region of interest (ROI). All
information lower than background was ignored during further
image analysis.
Coverage calculation. The threshold was defined as above.
The area of the ROI in the max-intensity Z-projection image was
calculated using ImageJ. The percent coverage was defined as the





where COV is the coverage, DAT is the area of the ROI obtained
at threshold, A0 is the area of the FOV. If the ROI is not selected
at threshold, the coverage is undervalued (Figure 1H).
In fact, different threshold values were obtained in different
pairs of control and negative control images for the same staining,
but no significant difference was found between the coverage using
those different threshold values.
Average thickness calculation. The area and length of the
bounding rectangle of the ROI in XZ-and YZ-slices were also
calculated using the same threshold values as above (Figure 1I and





where TAV is the average thickness, and A’ and respectively
represent the area and the length of the ROI obtained at
threshold.
Junctional thickness calculation. Combining the nuclei
staining image (Figure 1C) and the max-intensity Z-projection
image (Figure 1F), the outlines of cell-cell junctions are found.
Then, the junction positions in XZ-and YZ-slices can be indicated
(Figure 1D and E). Figure 1K shows a partial enlargement of the
XZ-slice image. Junctional thickness was determined using a line
in the z direction at the junction position in the XZ-and YZ-slices.
The intensities of pixels along the selected lines were obtained
using the ImageJ plot profile tool. As shown in Figure1L, the
ordinate is the pixel intensity and the abscissa is the distance along
the line. According to the SUSAN edge finding algorithm [41], the
half maximum intensity value was employed as the second
threshold (2nd threshold) for junctional thickness detection [42,43].
If the 2nd threshold value was lower than the background
threshold value, the line was considered empty so that the
junctional thickness was equal to zero. However, if the 2nd
threshold was above the background threshold, the width of the
intensity-distance curve at the 2nd threshold was taken as the
junction thickness. The interval between slices defined the pixel
dimension in the Z direction, so that the lowest thickness that
could be detected was either 0.3 or 0.36 mm.
For the correction, all of the 2nd threshold values were recorded.
The signal-to-noise ratio was defined as the average 2nd threshold
value divided by the background threshold value (noise value)
Figure 4. The distribution of HA on RFPECs after 2 hr hyaluronidase treatment. (A) top: Z-projection; bottom: cross-sectional images of
stack along the dashed line. The arrow head indicates the cell-cell junction. Scale bar: 20 mm. (B) The changes in coverage; (C) the average thickness;
(D) the junction thickness. **P,0.01.
doi:10.1371/journal.pone.0043168.g004
Endothelial Glycocalyx Structure
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[42]. Lines with a signal-to-noise ratio below 2.5 [42] overesti-
mated junctional thicknesses and were not used for further
analysis.
Enzyme spatial digestibility. The coverage and thickness
of glycocalyx components (HS, CS, HA, and BSA) as a function of
enzyme concentration (x) were curve fit with exponential
equations: fC xð Þ and fT xð Þ. To further analyze the changes in
spatial distribution of glycocalyx components after corresponding
enzyme removal, we calculated the enzyme spatial digestibility (d).










’ xð Þ and fT ’ xð Þ are the first derivatives of fC xð Þ and fT xð Þ
that denote the coverage (%) and thickness (mm) of the glycocalyx
component, respectively. x0 is the starting enzyme concentration.
Figure 5. The quantification of HS, CS, and albumin on RFPECs after 2 hr hyaluronidase treatment. (A)–(C) The changes in the coverage,
the average thickness, and the junction thickness of HS; (D)–(F) CS; (G)–(I) adsorbed albumin.
doi:10.1371/journal.pone.0043168.g005
Endothelial Glycocalyx Structure
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Statistical Analysis
Data are presented as means 6 SD obtained from at least three
independent experiments. The images for coverage and average
thickness calculations were obtained from respectively, at least 18
max-intensity Z-projection images and 180 X-and Y-slices. For
junctional thickness calculations, lines were selected for at least 180
junction positions from the X-and Y-slices. Statistical analysis was
performed by one-way analysis of variance (ANOVA) with either
the least significant difference (LSD) test or Tamhane’s T2 test
(depending on Levene’s statistic for homogeneity of variance) using
the SPSS 20.0 software package. Differences in means were
considered significant if P,0.05. All images shown in the present
paper had the background subtracted unless indicated otherwise.
Results and Analysis
Enzymatic Removal of HS by Heparinase III
The dose-dependent removal of HS by heparinase III is shown
in Figure 2. The initial coverage of HS on RFPECs (83.363.2%,
control) was significantly decreased to 72.163.5, 65.063.8,
42.064.3, 14.565.1, 5.860.9, and 2.661.0% in the presence of
15, 45, 135, 405, 1215 and 3645 mU/mL heparinase III,
respectively. The average thickness and junctional thickness of
HS (2.260.6 and 3.260.4 mm, respectively) were significantly
decreased when the heparinase III concentrations were above the
45 mU/mL. At the highest enzyme concentration, the average
thickness of HS decreased by 54.9%, and the junctional thickness
of HS decreased by 55.0%. There were no significant changes in
coverage, average thickness and junctional thickness between 1215
and 3645 mU/mL, indicating that 1215 mU/mL heparinase III
could remove most of the HS.
The equations describing the coverage and average thickness of
HS against the concentration of heparinase III (x), were given by
fC xð Þ~4:22z76:60:e{0:005x ðR2 ¼ 0:99Þð4Þ
fT xð Þ~1:02z1:17:e{0:005x ðR2 ¼ 0:99Þð5Þ
The enzyme spatial digestibility (d) was 1.73, independent of
enzyme concentration, indicating that the reduction of HS in
coverage was 1.73 times greater than in average thickness.
HA after Heparinase III Treatment
The coverage, average thickness, and junctional thickness of HA
were 88.866.4%, 1.960.3 and 2.160.3 mm, respectively after
treatment with 1215 mU/mL heparinase III (Figure 3A–C; Figure
S1A shows immuno-staining images). There were no statistically
significant changes in the coverage, average thickness, and
junctional thickness of HA after heparinase III treatment at this
dose that removed virtually all of the HS, suggesting little
interaction between HA and HS.
CS Clusters Near the Junctions after Heparinase III
Treatment
The structure of CS after heparinase III treatment is shown in
Figure 3D–F (Figure S1B shows immuno-staining images). Before
enzyme treatment, the coverage, average thickness and junctional
thickness of CS were 87.265.3%, 1.260.2 and 1.760.3 mm,
respectively. After heparinase III treatment at a high dose, the
coverage of CS had no significant change, but the average
Figure 6. The distribution of CS on RFPECs after 2 hr chondroitinase ABC treatment. (A) top: Z-projection; bottom: cross-sectional images
of stack along the dashed line. The arrow head indicates the cell-cell junction. Scale bar: 20 mm. (B) The changes in coverage; (C) the average
thickness; (D) the junction thickness. **P,0.01.
doi:10.1371/journal.pone.0043168.g006
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thickness and junctional thickness of CS actually increased
significantly by 7.3% and 26.1%, respectively, in the presence of
1215 mU/mL heparinase III. These results indicate that CS
clusters near the junctions after removal of HS. There was no
evidence of CS collapse as HS was depleted.
Adsorbed Albumin after Heparinase III Treatment
The coverage, average thickness, and junctional thickness of
albumin before enzyme treatment were 93.165.4%, 1.860.5 and
2.660.6 mm, respectively (Figure 3G–I; Figure S1C shows
immuno-staining images). There were no significant changes in
coverage, average thickness and junctional thickness after hepa-
rinase III treatment at both 135 and 1215 mU/mL.
Enzymatic Removal of HA by Hyaluronidase
The dose-dependent removal of HA by hyaluronidase is shown
in Figure 4. Before enzyme treatment, the coverage, average
thickness and junctional thickness of HA were 87.763.3%,
1.960.3 and 2.160.2 mm, respectively. The coverage, average
thickness, and junctional thickness of HA were significantly
decreased by 41.6, 26.9, and 25.0%, respectively in the presence
of 1.5 U/mL hyaluronidase, and by 93.1, 56.0 and 53.3%,
Figure 7. The quantification of HA, HS, and albumin on RFPECs after 2 hr chondroitinase ABC treatment. (A)–(C) The changes in the
coverage, the average thickness, and the junction thickness of HA; (D)–(F) HS; (G)–(I) adsorbed albumin. **P,0.01.
doi:10.1371/journal.pone.0043168.g007
Endothelial Glycocalyx Structure
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respectively in the presence of 4.5 U/mL hyaluronidase. There
were no significant changes in coverage, average thickness, and
junctional thickness between 4.5 and 13.5 U/mL hyaluronidase,
suggesting that 4.5 mU/mL could remove most of the HA.
The equations describing the coverage and average thickness of
HA as a function of hyaluronidase concentration (x), were given by
fC xð Þ~3:12z86:41:e{0:53x ðR2 ¼ 0:92Þð6Þ
fT xð Þ~0:95z1:16:e{0:53x ðR2 ¼ 0:96Þð7Þ
The enzyme spatial digestibility (d) was 1.60, independent of
enzyme concentration, indicating that the decrease of HA in
coverage was 1.60 times greater than in average thickness.
The Structure of HS, CS and Adsorbed Albumin after
Hyaluronidase Treatment
No significant differences were found between the hyaluroni-
dase-treated and control groups for the coverage, average
thickness, and junctional thickness of HS, CS and albumin
(Figure 5, Figure S2 shows immuno-staining images).
Enzymatic Removal of CS by Chondroitinase ABC
The removal of CS by chondroitinase ABC was also dose-
dependent (Figure 6). The initial coverage of CS on RFPECs
(86.565.6%) was significantly decreased to 61.266.5, 36.864.6,
19.166.3, and 16.565.4% in the presence of 15, 45, 135, and
405 mU/mL chondroitinase ABC, respectively. The average
thickness (1.260.2 mm) was significantly decreased by 8.7, 19.0,
26.7, and 31.3%, respectively, in the presence of 15, 45, 135,
and 405 mU/mL chondroitinase ABC. The junctional thickness
(1.860.3 mm) was significantly decreased by 13.7, 26.0, 40.8,
and 42.8%, respectively, in the presence of 15, 45, 135, and
405 mU/mL chondroitinase ABC. There were no significant
changes in the coverage, average thickness, and junctional
thickness between 135 and 405 mU/mL chondroitinase ABC,
suggesting that the 135 mU/mL could remove most of the CS.
The equations describing the coverage and average thickness of
CS as a function of chondroitinase ABC concentration (x), were
given by
fC xð Þ~17:04z69:08:e{0:02x ðR2 ¼ 0:99Þð8Þ
fT xð Þ~1:03z0:75:e{0:02x ðR2 ¼ 0:99Þð9Þ
The enzyme spatial digestibility (d) was 1.28, independent of
enzyme concentration, indicating that the reduction of CS in
coverage was 1.28 times greater than in average thickness.
Degradation of HA by Chondroitinase ABC
The HA was also degraded by chondroitinase ABC as shown in
Figure 7A–C (Figure S3A shows immuno-staining images). The
coverage, average thickness, and junctional thickness of HA were
decreased by 90.9, 54.8, and 53.2%, respectively, in the presence
of 15 mU/mL chondroitinase ABC. In the presence of 45 mU/
mL chondroitinase ABC induced no further changes. Because a
low dose of chondroitinase ABC almost completely cleaved HA,
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clear that the coverage was reduced more extensively than the
average thickness.
The Structure of HS after Chondroitinase ABC Treatment
To investigate whether chondroitinase ABC would affect the
glycocalyx structure, the visualization of HS was performed in the
presence of 0, 15 and 405 mU/mL chondroitinase ABC
(Figure 7D–F; Figure S3B shows immuno-staining images). The
coverage, average thickness, and junctional thickness of HS were
not significantly changed, suggesting that direct removal of CS
does not affect the HS.
The Structure of Adsorbed Albumin after Chondroitinase
ABC Treatment
Figure 7G–I (Figure S3C displays immuno-staining images)
shows the changes of adsorbed albumin after chondroitinase ABC
treatment. The coverage of albumin was not changed significantly.
In the presence of 15 and 405 mU/mL chondroitinase ABC, the
changes in the average and junctional thickness were statistically
significant, although the changes were relatively small (15%
reduction of the average thickness and 20.8% reduction of the
junctional thickness at 405 mU/mL).
Discussion
We have, in recent years, analyzed the function and organiza-
tion of the EGL on various cells and animal tissues [16,31,44,45].
Modifications of EC function after enzyme treatment of the EGL,
include mechanotransduction [3,25], permeability [2,11] and
adhesion [46]. But, the structural changes of the EGL after
enzyme treatment that may underlie the functional modifications
have not been thoroughly investigated as summarized in Table 1.
A review of this table demonstrates that reductions of fluorescence
intensity and thickness of the EGL have been observed at various
doses of enzyme using several different visualization methods. But
the effects of specific enzymes on off-target components have not
been determined, leaving the structure of the EGL unclear. The
present study demonstrates the organization and spatial distribu-
tion characteristics of the EGL after removal of prominent GAGs.
The interaction of GAGs and their contributions to structural
stability of the EGL are revealed. The study was based on
RFPECs because these ECs displayed the most immune-positivity
over the complete series of GAG antibodies employed.
The control experiments labeling the glycocalyx components on
RFPECs using confocal laser scanning microscopy with immuno-
fluorescence staining in the absence of enzyme showed that the
coverage of HS, CS, HA, and adsorbed albumin was 83.363.2,
87.265.3, 87.663.3 and 93.165.4%, respectively, indicating
similar high levels of coverage of each GAG. But we did not do
any co-staining for more than one GAG or albumin. It is very
likely that the area not covered by a particular GAG/albumin (7%
to 17%) is covered by one or more of the other GAGs/albumin.
Co-staining studies were not performed as the best secondary
antibodies were all based on Alexa Fluor 488. The same approach
used on the common carotid artery of C57BL/6J (B6) mice
showed a similar coverage of HS and HA, which respectively were
8669 and 8566% [47]. Our results show that the average
thickness of HS, CS, HA, and adsorbed albumin on RFPECs was
2.260.6, 1.260.2, 1.960.3 and 1.860.5 mm, and the junctional
thickness was 3.260.4, 1.760.3, 2.160.3 and 2.660.6 mm,
respectively. A nonuniform thickness of individual GAGs on
RFPECs was found, which is similar to others [42,43,48].
Although the detailed ultrastructure of the EGL and its
components is difficult to discern from these immunofluorescence
staining-confocal microscopy studies, since the coverages and
thicknesses of all components were similar, we can hypothesize
that the GAG components and adsorbed albumin were well
integrated within the structure of the EGL.
Heparinase III, hyaluronidase, and chondroitinase ABC, were
used to remove respective GAGs by varying the incubation
concentration for 2 hr. Heparinase III cleaves HS exclusively,
while hyaluronidase from Streptomyces hyalurolyticus is specific for
HA. The chondroitinase ABC (EC 4.2.2.4) degrades both CS and
HA. It has been reported that HA degradation by chondroitinase
ABC is most effective at a pH near 6.8 [39], and less efficient at
pH 8.6 [49,50] or 9.1 [51,52], while according to the instructions
from the manufacturer (Sigma), chondroitinase ABC degrades HA
and CS optimally at pH 6.2 and 8.0. To be consistent with the cell
Figure 8. Hypothesis–Experimental results–Conclusion. Left: Our hypothesis of an interacting mesh of GAGs and albumin. Middle: A summary
of the results of our experiments: removal of HS (heparinase III), HA (hyaluronidase), or both CS and HA (chondroitinase ABC) did not reduce the
coverage or thickness of any of the remaining components, indicating that no individual component (HS, HA or CS) is required to stabilize the EGL.
Right: The overarching conclusion of our study: GAG components do not interact but do provide binding sites for albumin.
doi:10.1371/journal.pone.0043168.g008
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culture conditions, all enzymes were prepared at pH 7.3. Our
results demonstrate that the effect of heparinase III, hyaluronidase,
and chondroitinase ABC on their target GAGs is dose-dependent.
1215 mU/mL heparinase III removes most of the HS (Figure 2);
4.5 U/mL hyaluronidase and 15 mU/mL chondroitinase ABC
remove most of the HA (Figures 4 and 6); and 405 mU/mL
chondroitinase ABC removes most of the CS (Figure 6). The
observation that chondroitinase removes both CS and HA has
been reported in other studies [39,52]. The degradation of HA by
chondroitinase occurs at a substantially lower concentration of
enzyme than the degradation of CS.
To further analyze the changes in spatial distribution of GAGs
after corresponding enzyme treatment, we calculated the enzyme
spatial digestibility. We found that the enzyme spatial digestibility
of HS, CS, and HA were 1.73, 1.60, and 1.28, respectively,
indicating that the remaining fractions of target component did
not collapse after reduction in coverage.
After nearly complete removal HS by 135 and 1215 mU/mL
heparinase III, the HA and adsorbed albumin were not
significantly different from the control state in the absence of
enzyme (Figures 3A–C and G–I). The average and junctional
thickness of CS actually significantly increased by 7.3 and 26.1%,
respectively, in the presence of 1215 mU/mL heparinase III
(Figure 3E and F). These data show that CS clusters near the
junctions after removal of HS and that removal of HS does not
lead to the removal or collapse of any other component, suggesting
that the stability of the EGL is independent of HS.
After almost complete removal of HA by 1.5 and 4.5 U/mL
hyaluronidase, HS, CS, and adsorbed albumin were not affected
in their coverage and average or junctional thickness (Figure 5).
These data indicate that removal of HA does not lead to the
removal or collapse of any other component, indicating that EGL
stability is independent of HA. However, 15 and 405 mU/mL
chondroitinase ABC that degraded most of HA and CS caused the
thickness of adsorbed albumin to be decreased by a relatively small
but statistically significant amount (Figure 7H and I). Taken
together, these results indicate that the decrease in thickness of
adsorbed albumin by chondroitinase is due to the degradation of
both CS and HA, removing many binding sites for the capture of
albumin. Surprisingly, neither hyaluronidase nor chondroitinase
ABC affected the organization of HS (Figures 5A–C and 7D–F).
In summary, the structural changes of the EGL after various
enzyme treatments have been studied systematically to improve
our understanding of the organization of this gel-like mesh. The
following conclusions have been extracted from the data:
1. The high level of coverage of individual GAGs and adsorbed
albumin in the absence of enzyme indicate that all GAGs and
adsorbed albumin are well inter-mixed within the structure of
the EGL.
2. Structural changes of individual GAGs are dependent upon the
dose of their specific enzyme, and decrease much more in
coverage than in thickness after enzyme treatment.
3. The removal of a single GAG component by a specific enzyme
does not degrade or collapse other GAGs, suggesting a
structural stability of the EGL that is independent of the
interaction between individual GAG components. A summary
of our results in this regard is presented in schematic form in
Figure 8. There we show our hypothesis of an interacting mesh
of GAGs and albumin at the left. The results of our
experiments are summarized in the middle showing that
removal of either HS or HA did not reduce the coverage or
thickness of any of the remaining components, indicating that
neither HS nor HA is required to stabilize the EGL. Although
removal of CS and HA with chondroitinase did not reduce the
coverage or thickness of HS, it did reduce adsorbed albumin,
although the effect was not large. The overarching conclusion
of our study is depicted at the right of Figure 8 that suggests
non-interacting GAG components that each provides binding
sites for albumin. The influence of albumin concentration in
the media on the stability of GAG components has not been
investigated in the present study.
Supporting Information
Figure S1 The immunofluorescence staining images of
CS, HA, and adsorbed albumin on heparinase III-
treated RFPECs. (A) CS; (B) HA; (C) adsorbed albumin. In
each group, Top: Z-projection; bottom: cross-sectional images of
stack along the dashed line. The arrow head indicates the cell-cell
junction. Scale bar: 20 mm.
(TIF)
Figure S2 The immunofluorescence staining images of
HS, CS, and adsorbed albumin on hyaluronidase-
treated RFPECs. (A) HS; (B) CS; (C) adsorbed albumin. In
each group, Top: Z-projection; bottom: cross-sectional images of
stack along the dashed line. The arrow head indicates the cell-cell
junction. Scale bar: 20 mm.
(TIF)
Figure S3 The immunofluorescence staining images of
HA, HS, and adsorbed albumin on chondroitinase ABC-
treated RFPECs. (A) HA; (B) HS; (C) adsorbed albumin. In
each group, Top: Z-projection; bottom: cross-sectional images of
stack along the dashed line. The arrow head indicates the cell-cell
junction. Scale bar: 20 mm.
(TIF)
Figure S4 Effects of heparinase III on 10E4 epitope and
Hepss-1 epitope anti-HS antibody–labeled HS. Both 10E4
epitope and HepSS-1 epitope anti-HS antibody–labeled HS were
also almost completely removed by 1215 mU/mL heparinase III
(2 hr). **P,0.01.
(TIF)
Figure S5 The immunofluorescence staining images of
CS using the CS-56 antibody. The strong CS-56 immunopo-
sitivity remained on the cell surface after 1215 mU/mL
chondroitinase ABC digestion. A representative experiment is
shown (background was removed). Scale bar: 20 mm.
(TIF)
Figure S6 The immunofluorescence staining images of
HA using the HABP from US biological. Using the HABP
from US biological, HA staining was actually enhanced by
hyaluronidase treatment at 4.5 and 13.5 U/ml. A representative
experiment is shown. Scale bar: 20 mm.
(TIF)
Discussion S1 Supplementary Discussion.
(DOC)
Author Contributions
Conceived and designed the experiments: YZ JMT. Performed the
experiments: YZ. Analyzed the data: YZ JMT. Contributed reagents/
materials/analysis tools: YZ EEE BMF JMT. Wrote the paper: YZ JMT.
Endothelial Glycocalyx Structure
PLOS ONE | www.plosone.org 13 August 2012 | Volume 7 | Issue 8 | e43168
References
1. Pries AR, Secomb TW, Gaehtgens P (2000) The endothelial surface layer.
Pflugers Arch 440: 653–666.
2. Tarbell JM (2010) Shear stress and the endothelial transport barrier. Cardiovasc
Res 87: 320–330.
3. Tarbell JM, Ebong EE (2008) The endothelial glycocalyx: a mechano-sensor
and-transducer. Sci Signal 1: pt8.
4. Weinbaum S, Tarbell JM, Damiano ER (2007) The structure and function of
the endothelial glycocalyx layer. Annu Rev Biomed Eng 9: 121–167.
5. Kolset SO, Prydz K, Pejler G (2004) Intracellular proteoglycans. Biochem J 379:
217–227.
6. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG (2007)
The endothelial glycocalyx: composition, functions, and visualization. Pflugers
Arch 454: 345–359.
7. Rapraeger A (1989) Transforming growth factor (type beta) promotes the
addition of chondroitin sulfate chains to the cell surface proteoglycan (syndecan)
of mouse mammary epithelia. J Cell Biol 109: 2509–2518.
8. Vogl-Willis CA, Edwards IJ (2004) High-glucose-induced structural changes in
the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothelial
cells. Biochim Biophys Acta 1672: 36–45.
9. Singh A, Friden V, Dasgupta I, Foster RR, Welsh GI, et al. (2011) High glucose
causes dysfunction of the human glomerular endothelial glycocalyx. Am J Physiol
Renal Physiol 300: F40–48.
10. Laurent TC, Fraser JR (1992) Hyaluronan. FASEB J 6: 2397–2404.
11. Curry FE, Adamson RH (2012) Endothelial glycocalyx: permeability barrier and
mechanosensor. Ann Biomed Eng 40: 828–839.
12. Eggli PS, Graber W (1995) Association of hyaluronan with rat vascular
endothelial and smooth muscle cells. J Histochem Cytochem 43: 689–697.
13. Friden V, Oveland E, Tenstad O, Ebefors K, Nystrom J, et al. (2011) The
glomerular endothelial cell coat is essential for glomerular filtration. Kidney Int
79: 1322–1330.
14. Adamson RH, Clough G (1992) Plasma proteins modify the endothelial cell
glycocalyx of frog mesenteric microvessels. J Physiol 445: 473–486.
15. Witte S (1988) The influence of the fibrinolytic system on the affinity of
fibrinogen for the endothelial-plasma interface. Thromb Res 52: 111–117.
16. Ebong EE, Macaluso FP, Spray DC, Tarbell JM (2011) Imaging the endothelial
glycocalyx in vitro by rapid freezing/freeze substitution transmission electron
microscopy. Arterioscler Thromb Vasc Biol 31: 1908–1915.
17. Delvos U, Preissner KT, Muller-Berghaus G (1985) Binding of fibrinogen to
cultured bovine endothelial cells. Thromb Haemost 53: 26–31.
18. Duan W, Paka L, Pillarisetti S (2005) Distinct effects of glucose and glucosamine
on vascular endothelial and smooth muscle cells: evidence for a protective role
for glucosamine in atherosclerosis. Cardiovasc Diabetol 4: 16.
19. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, et al. (1999)
Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:
729–777.
20. Becker BF, Chappell D, Jacob M (2010) Endothelial glycocalyx and coronary
vascular permeability: the fringe benefit. Basic Res Cardiol 105: 687–701.
21. Mulivor AW, Lipowsky HH (2004) Inflammation-and ischemia-induced
shedding of venular glycocalyx. Am J Physiol Heart Circ Physiol 286: H1672–
1680.
22. Van Teeffelen JW, Brands J, Stroes ES, Vink H (2007) Endothelial glycocalyx:
sweet shield of blood vessels. Trends Cardiovasc Med 17: 101–105.
23. Marechal X, Favory R, Joulin O, Montaigne D, Hassoun S, et al. (2008)
Endothelial glycocalyx damage during endotoxemia coincides with microcircu-
latory dysfunction and vascular oxidative stress. Shock 29: 572–576.
24. Nelson A, Berkestedt I, Schmidtchen A, Ljunggren L, Bodelsson M (2008)
Increased levels of glycosaminoglycans during septic shock: relation to mortality
and the antibacterial actions of plasma. Shock 30: 623–627.
25. Pahakis MY, Kosky JR, Dull RO, Tarbell JM (2007) The role of endothelial
glycocalyx components in mechanotransduction of fluid shear stress. Biochem
Biophys Res Commun 355: 228–233.
26. Gao L, Lipowsky HH (2010) Composition of the endothelial glycocalyx and its
relation to its thickness and diffusion of small solutes. Microvasc Res 80: 394–
401.
27. Henry CB, Duling BR (1999) Permeation of the luminal capillary glycocalyx is
determined by hyaluronan. Am J Physiol 277: H508–514.
28. Desjardins C, Duling BR (1990) Heparinase treatment suggests a role for the
endothelial cell glycocalyx in regulation of capillary hematocrit. Am J Physiol
258: H647–654.
29. Constantinescu AA, Vink H, Spaan JA (2003) Endothelial cell glycocalyx
modulates immobilization of leukocytes at the endothelial surface. Arterioscler
Thromb Vasc Biol 23: 1541–1547.
30. Lipowsky HH (2012) The endothelial glycocalyx as a barrier to leukocyte
adhesion and its mediation by extracellular proteases. Ann Biomed Eng 40: 840–
848.
31. Nikmanesh M, Shi Z-D, Tarbell JM (2012) Heparan sulfate proteoglycan
mediates shear stress-induced endothelial gene expression in mouse embryonic
stem cell-derived endothelial cells. Biotechnology and Bioengineering 109: 583–
594.
32. Sorensson J, Ohlson M, Haraldsson B (2001) A quantitative analysis of the
glomerular charge barrier in the rat. Am J Physiol Renal Physiol 280: F646–656.
33. Sorensson J, Ohlson M, Lindstrom K, Haraldsson B (1998) Glomerular charge
selectivity for horseradish peroxidase and albumin at low and normal ionic
strengths. Acta Physiologica Scandinavica 163: 83–91.
34. Ohlson M, Sorensson J, Haraldsson B (2001) A gel-membrane model of
glomerular charge and size selectivity in series. Am J Physiol Renal Physiol 280:
F396–405.
35. Marcum JA, Rosenberg RD (1985) Heparinlike molecules with anticoagulant
activity are synthesized by cultured endothelial cells. Biochem Biophys Res
Commun 126: 365–372.
36. Thi MM, Tarbell JM, Weinbaum S, Spray DC (2004) The role of the glycocalyx
in reorganization of the actin cytoskeleton under fluid shear stress: a ‘‘bumper-
car’’ model. Proc Natl Acad Sci U S A 101: 16483–16488.
37. Chappell D, Jacob M, Rehm M, Stoeckelhuber M, Welsch U, et al. (2008)
Heparinase selectively sheds heparan sulphate from the endothelial glycocalyx.
Biol Chem 389: 79–82.
38. Kaneiwa T, Mizumoto S, Sugahara K, Yamada S (2010) Identification of
human hyaluronidase-4 as a novel chondroitin sulfate hydrolase that
preferentially cleaves the galactosaminidic linkage in the trisulfated tetrasaccha-
ride sequence. Glycobiology 20: 300–309.
39. Yamagata T, Saito H, Habuchi O, Suzuki S (1968) Purification and properties
of bacterial chondroitinases and chondrosulfatases. J Biol Chem 243: 1523–
1535.
40. Hamai A, Hashimoto N, Mochizuki H, Kato F, Makiguchi Y, et al. (1997) Two
distinct chondroitin sulfate ABC lyases. An endoeliminase yielding tetrasaccha-
rides and an exoeliminase preferentially acting on oligosaccharides. J Biol Chem
272: 9123–9130.
41. Smith SM, Brady JM (1997) SUSAN–A new approach to low level image
processing. International journal of computer vision 23: 45–78.
42. Reitsma S, oude Egbrink MG, Vink H, van den Berg BM, Passos VL, et al.
(2011) Endothelial glycocalyx structure in the intact carotid artery: a two-photon
laser scanning microscopy study. J Vasc Res 48: 297–306.
43. Yen WY, Cai B, Zeng M, Tarbell JM, Fu BM (2012) Quantification of the
endothelial surface glycocalyx on rat and mouse blood vessels. Microvasc Res
83: 337–346.
44. Dancu MB, Tarbell JM (2007) Coronary endothelium expresses a pathologic
gene pattern compared to aortic endothelium: correlation of asynchronous
hemodynamics and pathology in vivo. Atherosclerosis 192: 9–14.
45. Shi ZD, Tarbell JM (2011) Fluid flow mechanotransduction in vascular smooth
muscle cells and fibroblasts. Ann Biomed Eng 39: 1608–1619.
46. Lipowsky HH (2011) Protease Activity and the Role of the Endothelial
Glycocalyx in Inflammation. Drug Discov Today Dis Models 8: 57–62.
47. van den Berg BM, Spaan JA, Vink H (2009) Impaired glycocalyx barrier
properties contribute to enhanced intimal low-density lipoprotein accumulation
at the carotid artery bifurcation in mice. Pflugers Arch 457: 1199–1206.
48. Stevens AP, Hlady V, Dull RO (2007) Fluorescence correlation spectroscopy can
probe albumin dynamics inside lung endothelial glycocalyx. Am J Physiol Lung
Cell Mol Physiol 293: L328–335.
49. Derby MA, Pintar JE (1978) The histochemical specificity of Streptomyces
hyaluronidase and chondroitinase ABC. Histochem J 10: 529–547.
50. Tennyson VM, Payette RF, Rothman TP, Gershon MD (1990) Distribution of
hyaluronic acid and chondroitin sulfate proteoglycans in the presumptive
aganglionic terminal bowel of ls/ls fetal mice: an ultrastructural analysis. J Comp
Neurol 291: 345–362.
51. Koshiishi I, Takenouchi M, Hasegawa T, Imanari T (1998) Enzymatic method
for the simultaneous determination of hyaluronan and chondroitin sulfates using
high-performance liquid chromatography. Anal Biochem 265: 49–54.
52. Grondahl F, Tveit H, Akslen-Hoel LK, Prydz K (2011) Easy HPLC-based
separation and quantitation of chondroitin sulphate and hyaluronan disaccha-
rides after chondroitinase ABC treatment. Carbohydr Res 346: 50–57.
53. Haldenby KA, Chappell DC, Winlove CP, Parker KH, Firth JA (1994) Focal
and regional variations in the composition of the glycocalyx of large vessel
endothelium. J Vasc Res 31: 2–9.
54. Barker AL, Konopatskaya O, Neal CR, Macpherson JV, Whatmore JL, et al.
(2004) Observation and characterisation of the glycocalyx of viable human
endothelial cells using confocal laser scanning microscopy. Physical Chemistry
Chemical Physics 6: 1006–1011.
55. van den Berg BM, Vink H, Spaan JA (2003) The endothelial glycocalyx protects
against myocardial edema. Circ Res 92: 592–594.
56. Wright CS (1984) Structural comparison of the two distinct sugar binding sites in
wheat germ agglutinin isolectin II. J Mol Biol 178: 91–104.
Endothelial Glycocalyx Structure
PLOS ONE | www.plosone.org 14 August 2012 | Volume 7 | Issue 8 | e43168
